Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model

• DOI: 10.2147/copd.s124420
• Publication Date: 2017-03-26T22:48:58Z
• Authors: Michele Wilson; Jeetvan Patel; Amber Coleman; Cheryl McDade; Richard H Stanford; Stephanie Earnshaw
• Keywords: Lama; Bronchodilator Agents

Background: Bronchodilators such as long-acting muscarinic antagonists (LAMAs) and β 2 -agonists (LABAs) are central to the pharmacological management of COPD. Dual bronchodilation with umeclidinium/vilanterol (UMEC/VI; 62.5/25 µg) is a novel LAMA/LABA combination approved for maintenance treatment patients Objective: The objective this study was assess cost-effectiveness UMEC/VI compared tiotropium (TIO) 18 µg, open dual LAMA + LABA treatment, or no bronchodilator in moderate very severe Methods: A Markov model developed estimate costs outcomes associated COPD (GSK number: HO-13-13411). Clinical efficacy, costs, utilities, mortality obtained from published literature were used inputs. Costs presented US dollars based on 2015 prices. outputs total drug other medical number exacerbations, quality-adjusted life-years (QALYs). discounted at 3% annual rate. Incremental ratios calculated. One-way probabilistic sensitivity analyses conducted effects changing parameters uncertainty results. Results: lower lifetime ($82,344) TIO ($88,822), ($114,442), ($86,751). Fewer exacerbations predicted occur treatment. provided an 0.11 0.25 increase QALYs such, dominated these analyses. Sensitivity confirmed that results robust. Conclusion: suggest would be dominant less costly than Keywords: umeclidinium, vilanterol, cost-effectiveness, tiotropium,